Aktuelles Testspektrum Molekularpathologie
Die dazugehörigen Auftragsformulare finden sich unter:
Für Fachkollegen Formulare zum Download
Molekulare Diagnostik genetischer und epigenetischer Veränderungen bei soliden Tumoren
Die molekulare Signatur bestimmt wesentlich das Erscheinungsbild eines Tumors. Der Anteil genetischer Mutationen und epigenetischer Modifikationen sowie die resultierenden Expressionsmuster erlauben wichtige Rückschlüsse auf Prognose (Wachstums- und Invasionsfähigkeit, Metastasierungspotential) und Therapieoptionen (molekulare Targets) einer Tumorerkrankung.
Weitere Tests erfolgen gerne auf Anfrage.
- NGS-GenpanelGLIOM (hybrid capture): BCOR, BRAF, CDKN2A/B/C, EGFR, H3F3A, IDH1/2, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, PTEN, STAG2, TERT, TP53
- NGS-GenpanelGLIOM (hybrid capture): BRAF, CDKN2A/B, EGFR, IDH1/2, TERT, TP53
- NGS-Genpanel MENINGEOM (hybrid capture): AKT1, BAP1, BRAF, CDKN2A/B, IDH1/2, FGFR3, MET, NF2, NOTCH2, PIK3CA, PTEN, TERT, TP53
- ATRX: Expression (IHC)
- BRAF: V600-Mutationen (Pyrosequenzierung)
- CD44: Expression (IHC)
- EGFR: Genamplifikation (FISH)
- EGFR: Expression (IHC)
- EGFRvIII: Expression (IHC)
- ERBB2/HER2: Expression (IHC)
- H3F3A: Mutationen (Pyrosequenzierung)
- IDH1/IDH2: Mutationen (Pyrosequenzierung)
- Ki67: Expression (IHC)
- MGMT: Promotormethylierung (Pyrosequenzierung)
- P16: Expression (IHC)
- P53: Expression (IHC)
- PD-L1: Expression (IHC)
- PTEN: Expression (IHC)
- RET: Translokation (FISH, RNA-basiertes Realtime-Assay)
- TERT: Promotormutationen (Pyrosequenzierung)
- TP53: Mutationen Exons 2 - 11 (NGS)
- 1p/19q: Deletion (FISH)
- FGFR1: Genamplifikation (FISH)
- EGFR: Genamplifikation (FISH)
- ERBB2/HER2: Expression (IHC)
- PanTRK: Expression (IHC)
- NTRK1-3: Translokation/Fusion (FISH)
- PD-L1: Expression (IHC)
- RET: Translokationen/Fusionen (FISH, RNA basiertes Real-time Assay)
- NGS-Genpanel (hybrid capture): BRAF, EGFR, ERBB2, HRAS, KRAS, MET, NRAS, PIK3CA, RET, TERT, TP53
- NGS-Genpanel(OncoDeep): TMB (tumor mutational burden)
- NGS-Genpanel(OncoDeep): HRR-Gene (ATM, BRCA1/2, BRD4, BRIP1, CDK12, CHEK1/2, FANCA, FANCG, PALB2, PTEN, RAD51, RAD51B, RAD51C, RAD51D, RAD54L)
- NGS-Panel (hybrid capture): BRCA1/2
- BRAF: Mutationen V600 (Pyrosequenzierung)
- ERBB2/HER2: Expression (IHC)
- MMRP: Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- MSI: Fragmentanalyse (7 MS-Marker)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- PD-L1: Expression (IHC)
- RAS: KRAS-, NRAS-Mutationen (Pyrosequenzierung)
- RET: Mutationen (NGS)
- RET: Translokationen/Fusionen (FISH, RNA basiertes Real-time Assay)
- TERT: Promotormutationen (Pyrosequenzierung)
- NGS-Genpanel (hybrid capture): ALK, AKT1, BRAF, CDKN2A, CTNNB1, EGFR, ERBB2, HRAS, KEAP1, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET, ROS1, SMAD4, STK11, TP53
- NGS-Genpanel: 22 Fusionsgene: RNA-basiert (OncoDeep)
- ALK: Expression (IHC)
- ALK: Translokation/Fusion (FISH)
- ALK: Resistenzmutationen (NGS)
- BRAF: V600-Mutation (Pyrosequenzierung)
- DLL3: Expression (IHC)
- EGFR: Mutationen Exons 18, 19, 20 (einschl. T790M), 21 (Pyrosequenzierung)
- EGFR: Mutationen Exon 19-Deletion, L858R, T790M (Liquid Biopsy, ddPCR)
- EGFR: Genamplifikation (FISH)
- ERBB2/HER2: Expression (IHC)
- ERCC1: Expression (IHC)
- FGFR1: Genamplifikation (FISH)
- KRAS: G12C-Mutation (Pyrosequenzierung)
- MET: Exon 14-Skipping (RNA basiertes Real-time Assay)
- MET: Genamplifikation (FISH)
- NRG1: Translokation/Fusion (FISH)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- PD-L1: Expression (IHC)
- RAS: KRAS-, NRAS-Mutationen (Pyrosequenzierung)
- RET: Translokation (FISH, RNA basiertes Real-time Assay)
- ROS1: Expression (IHC)
- ROS1: Translokation (FISH, RNA basiertes Real-time Assay)
- NGS-Genpanel (hybrid capture): BRAF, BRCA1/2, ERBB2, FGFR2, IDH1/2, KRAS, NRAS
- BRAF: V600-Mutationen (Pyrosequenzierung)
- ERBB2/HER2: Genamplifikation (FISH)
- ERBB2/HER2: Expression (IHC)
- FGFR2: Mutationen und Translokationen (Realtime-Assay, FISH)
- IDH1/2: Mutationen (Pyrosequenzierung)
- MSI: Fragmentanalyse (7 MS-Marker)
- MMRP: Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay)
- NGS-Genpanel (hybrid capture): BRAF, BRCA1/2, ERBB2, KRAS, PIK3CA, TP53
- NGS-Genpanel (hybrid capture): BRCA1/2
- MSI: Promega-Panel (Fragmentanalyse: 5 MS-Marker), Idylla (High-Resolution Melting: 7 MS-Marker), Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- NTRK1-3: Expression (IHC), Translokation/Fusion (FISH, Idylla Realtime-Assay)
- NGS-Genpanel (hybrid capture): KIT, PDGFRA
- NGS-Genpanel(OncoDeep): KIT, PDGFRA, SDHA, SDHB, SDHC, SDHD
- ERBB2/HER2: Expression (IHC)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay)
- NGS-Genpanel(hybrid capture): AKT1, APC, BRAF, EGFR, ERBB2, HRAS, KRAS, MAP2K1, NRAS, PIK3CA, POLE, TP53
- NGS-Genpanel (hybrid capture): BRAF, ERBB2, HRAS, KRAS, NRAS
- APC: Mutationen (NGS)
- BRAF: Mutationen V600 (Pyrosequenzierung)
- DPYD: c.1905+1G>A, Exon 14-Skipping, (*2A); c.1679T>G, p.(I560S), (*13); c.2846A>T, p.(D949V); c.1236G>A (HaplotypB3) (Pyrosequenzierung)
- ERBB2/HER2: Expression (IHC)
- ERBB2/HER2: Genamplifikation (FISH)
- FGFR2: Translokation(FISH)
- MLH1: Promotormethylierung (Pyrosequenzierung)
- MMRP: Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- MSI: Fragmentanalyse (7 MS-Marker)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- PIK3CA: Mutationen Exons 4, 7, 9, 20 (Realtime-Assay, NGS)
- PIK3R1: Mutationen (NGS)
- POLE/POLD1: Mutationen (NGS)
- RAS: KRAS/NRAS-Mutationen(Pyrosequenzierung)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay)
- Claudin18.2: Expression (IHC)
- DPYD: Mutationen c.1905+1G>A, Exon 14-Skipping, (*2A); c.1679T>G, p.(I560S), (*13); c.2846A>T, p.(D949V); c.1236G>A (HaplotypB3) (Pyrosequenzierung)
- ERBB2/HER2: Expression (IHC)
- ERBB2/HER2: Genamplifikation (FISH)
- MMRP: Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- MSI: Fragmentanalyse (7 MS-Marker),
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- PD-L1: Expression (IHC)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay)
- TROP2: Expression (IHC)
- NGS-Genpanel (hybrid capture): AKT1, BRCA1/2, ERBB2, ESR1, PALB2, PIK3CA, PTEN
- NGS-Genpanel (hybrid capture): AKT1, PIK3CA, PTEN
- NGS-Genpanel (hybrid capture): BRCA1/2
- DPYD: c.1905+1G>A, Exon 14-Skipping, (*2A); c.1679T>G, p.(I560S), (*13); c.2846A>T, p.(D949V); c.1236G>A (HaplotypB3) (Pyrosequenzierung)
- ERBB2/HER2: Genamplifikation (FISH)
- ERBB2/HER2: Expression (IHC)
- FGFR1: Genamplifikation (FISH)
- MSI: Fragmentanalyse (7 MS-Marker)
- MMRP: Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- PIK3CA: Hotspot-Mutationen Exons 4, 7, 9, 20 (Realtime-Assay)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay)
- Liquid Biopsy:
- ESR1: Hotspot-Mutationen (Realtime-Assay)
- PIK3CA: Hotspot-Mutationen Exons 4, 7, 9, 20 (Realtime-Assay)
- ESR1 + PIK3CA: Mutationen (NGS)
- NGS-Panel (hybrid capture): BRAF, BRCA1/2, CTNNB1, KRAS, PIK3CA, POLE, POLD1, PTEN, TP53
- BRCA1/2: Mutationen (NGS)
- ERBB2/HER2: Expression (IHC)
- ERBB2/HER2: Genamplifikation (FISH)
- L1CAM (CD171): Expression (IHC)
- MLH1: Promotormethylierung (Pyrosequenzierung)
- MMRP: Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- MSI: Fragmentanalyse (7 MS-Marker)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- POLE/POLD1: Mutationen (NGS)
- P53: Expression (IHC)
- TP53: Mutationsanalyse Exons 2 - 11 (NGS)
- RET: Translokation (FISH, RNA-basiertes Realtime-Assay)
- NGS-Panel (hybrid capture): BRCA1/2
- HRD (Homologe Rekombinationsdefizienz): AmoyDX® HRD Focus Panel
- NTRK1-3: Expression (IHC), Translokation/Fusion (Realtime-Assay)
- NGS-Genpanel Melanom (hybrid capture): BRAF, CDKN2A, HRAS, KIT, KRAS, MAP2K1, NRAS, PDGFRA, PIK3CA, TERT
- BRAF: V600-Mutationen (Pyrosequenzierung)
- NRAS: Mutationen Exons 2, 3, 4 (Pyrosequenzierung)
- KIT: Mutationen Exons 9, 11, 13, 17 (NGS)
- NF1: Expression (IHC)
- ERBB2/HER2: Expression (IHC)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- PD-L1: Expression (IHC)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay)
- NGS-Genpanel Aderhautmelanom (hybrid capture): BAP1, CYSLTR2, EIF1AX, GNA11, GNAQ, KIT, NRAS, PLCB4, SF3B1
- HLA-Typisierung (in Koop. mit BSD)
- NGS-Genpanel (hybrid capture): BAP1, BRAF, CDKN2A, HRAS, KIT, MAP2K1, MAP3K8, NRAS, PTEN, TERT
- BRAF: Fusionen (FISH)
- 6q23 (MYB): Deletion (FISH)
- 6p25 (RREB1): Gain (FISH)
- 8q24 (MYC): Gain (FISH)
- 9p21 (CDKN2A): Deletion (FISH)
- 11q13 (CCND1): Gain (FISH)
- MSI: Fragmentanalyse (7 MS-Marker)
- MMRP: Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- ERBB2/HER2: Expression (IHC)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay)
- NGS-Genpanel (hybrid capture): BRCA1/2
- NGS-Genpanel (OncoDeep): HRR-Gene (ATM, BRCA1/2, BRD4, BRIP1, CDK12, CHEK1/2, FANCA, FANCG, PALB2, PTEN, RAD51, RAD51B, RAD51C, RAD51D, RAD54L)
- ERBB2/HER2: Expression (IHC)
- MMRP: Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- MSI: Fragmentanalyse (7 MS-Marker)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- PTEN: Expression (IHC)
- PTEN: Mutationsanalyse (NGS)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay
- NGS-Genpanel (hybrid capture): APC, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET, NRAS, PIK3CA, PTEN, TP53
- ERBB2/HER2: Expression (IHC)
- MMRP: Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- MSI: Fragmentanalyse (7 MS-Marker)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay)
- NRAS, PIK3CA, SF3B1, TERT, TP53
- ERBB2/HER2: Expression (IHC)
- FGFR2/3: Mutationen/Translokationen (Realtime-Assay)
- FGFR3: Genamplifikation (FISH)
- MMRP: Expression MLH1, PMS2, MSH2, MSH6 (IHC)
- MSI: Fragmentanalyse (7 MS-Marker)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- PD-L1: Expression (IHC)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay)
- TERT: Promotormutationen (Pyrosequenzierung)
- EWSR1: Translokation bei Ewing- und Klarzellsarkom (FISH)
- MDM2: Genamplifikation beim Liposarkom (FISH)
- SYT-SSX t(X;18): Translokation bei Ewing- und Klarzellsarkom (FISH)
- ERBB2/HER2: Expression (IHC)
- NTRK1-3: Translokation/Fusion (FISH)
- PanTRK: Expression (IHC)
- RET: Translokationen (FISH, RNA-basiertes Realtime-Assay)
Hämatopathologie
Dieser Teil der Pathologie, beschäftigt sich mit den Erkrankungen des blutbildenden Knochenmarks und der lymphatischen Organe. Gegenstand der Diagnostik sind dabei Knochenmarkpunktionszylinder (FFPE-Material), Ausstrichpräparate sowie peripheres und Knochenmarkblut. Die Diagnostik wird in enger Kooperation mit unseren Partnern durchgeführt.
- B-Zellklonalität: IGH-Schwerketten und IGK-Leichtketten (PCR-Fragmentanalyse)
- T-Zellklonalität: TCR (gamma und beta)-Rearrangements (PCR-Fragmentanalyse)
- Kappa/lambda-Leichtketten (CISH)
- NGS-Genpanel (hybrid capture): CARD11, CD79B, CREBBP, CXCR4, EZH2, GNA13, MYD88, PIM1, PRDM1, SOCS1, STAT6, TNFAIP3, TNFRSF14
- NGS-Genpanel (hybrid capture): ABCC9, ARID1A, ATM, BCOR, CARD11, CD28, DNMT3A, FYN, IDH2, JAK1/3, KMT2D, MSC, NCOR1, PLCG1, PTEN, RHOA, SETD1B, SETD2, STAT3, STAT5B, STAT6, TET2, TP53
- NGS-Genpanel (hybrid capture): ARID1A, BCOR, CARD11, CD28, DNMT3A, IDH2, JAK1/3, MSC, NCOR, PLCG1, RHOA, SETD2, STAT3/5b, TP53
- MYC: Translokation/Fusion (FISH)
- t(8;14) MYC/IGH: Translokation/Fusion (FISH)
- t(14;18) BCL2/IGH: Translokation/Fusion (FISH)
- BCL6: Translokation/Fusion (FISH)
- t(11;18) BIRC3/MALT1: Translokation/Fusion (FISH)
- 17p (TP53): Deletionen (FISH)
- t(11;14) CCND1/IGH: Translokation/Fusion (FISH
- MYD88: Exon 5 - Mutation p.L265P (Droplet Digital-PCR)
- CXCR4: Exon 2 - Mutation p.S338* (Droplet Digital-PCR)
- BRAF: V600-Mutation (Pyrosequenzierung)
- RAS: KRAS-/NRAS-Mutationen (Pyrosequenzierung)
- 17p (TP53): Deletionen (FISH)
- t(11;14) CCND1/IGH: Translokation/Fusion (FISH)
- CKS1B-CDKN2C: Amplifikation/Deletion (FISH)
- t(4;14) FGFR3/IGH: Translokation/Fusion (FISH)
- t(14;16) MAF/IGH: Translokation/Fusion (FISH)
- t(14;20) MAFB/IGH: Translokation/Fusion (FISH)
- NGS-GenpanelMyeloid (hybrid capture): ABL1, ASXL1,CALR, CBL, CEBPA, CSF3R, DNMT3A, EZH2, FLT3, IDH1/2, JAK2/3, KIT, KRAS, MPL, NPM1, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1
- NGS-Genpanel AML (hybrid capture): ASXL1, CEBPA, DNMT3A, FLT3, IDH1/2, KIT, NOTCH1, NPM1, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1
- NGS-Genpanel MDS-IPSS (hybrid capture): ASXL1, BCOR, CBL, CEBPA, DNMT3A, ETV6, EZH2, FLT3, IDH1/2, MLL/KMT2A, KRAS, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TP53, U2AF1
- NGS-Genpanel CMML (hybrid capture): ASXL1, CALR, EZH2, IDH1, JAK2, RUNX1, SRSF2, TET2
- AML-Genfusionen: AMLplex ( Fragmentanalyse)
- BCR/ABL: Translokation/Fusion (RT-PCR, FISH)
- BCR/ABL: MRD-Testung (Droplet Digital-PCR)
- CALR: Exon 9-Mutationen bei essent. Thrombozythämie (ET)und Polycythaemia vera (PMF) (Fragmentanalyse)
- CBFB: Translokation/Fusion (FISH)
- FGFR1: Genamplifikation (FISH), Translokation/Fusion (FISH)
- FLT3: Duplikation/Mutation (Fragmentanalyse/RFLP)
- IDH1: Hotspot-Mutationen (Pyrosequenzierung)
- JAK2: V617F-Mutation (Pyrosequenzierung, Droplet Digital-PCR)
- JAK2: Exon 12-Mutationen (Fragmentanalyse)
- KMT2A/MLL: Translokation/Fusion (FISH)
- MPL: W515L, W515K (Droplet Digital-PCR)
- NPM1: MRD-Diagnostik (RealTime-PCR)
- FIP1L1-PDGFRA: Translokation/Fusion (FISH)
- PDGFRB: Translokation/Fusion (FISH)
- 5q (EGR1): Deletion (FISH)
- 17p (TP53): Deletion (FISH)
- NGS-Genpanel (hybrid capture): ATM, BCOR, BIRC3, BRAF, BTK, EGR2, FBXW7, KRAS, NRAS, MYD88, NOTCH1, PLCG2, POT1, SAMHD1, SF3B1, TP53, XPO1
- TP53: Mutationsanalyse Exons 2-11 (NGS)
- IGH: IgHV-Mutationsstatus (NGS)
- 17p (TP53): Deletion (FISH)
- 11q (ATM): Deletion (FISH)
- 13q14: Deletion (FISH)
- Chr12: Chromosom 12-Trisomie (FISH)
- BRAF: Val600Glu/V600E - Mutation (Pyrosequenzierung)
- HFE: Mutationen C282Y, H63D, S65D (Pyrosequenzierung)
- NGS-Genpanel (hybrid capture): ASXL1, CBL, EZH2, IDH1/2, JAK2, KIT, KRAS, NRAS, RUNX1, SF3B1, SRSF2, TET2
- KIT: D816V-Mutation (Droplet Digital-PCR)
- KIT: Mutationen Exons 8 - 11, 13, 17, 18 (NGS)
- UBA1: Hotspot-Mutationen (droplet digital-PCR)
Molekulare Erregerdiagnostik bei Infektions- und Krebserkrankungen
Erreger (Viren, Bakterien, Protozoen, Pilze) können eine Vielzahl schwerwiegender Infektionen beim Menschen hervorrufen. Einige Vertreter von ihnen sind zudem an der Herausbildung von Tumorerkrankungen beteiligt (z.B. HPV, EBV, Helicobacter pylori).
- Bartonella: Nachweis (Realtime-PCR)
- Borrelia: Nachweis (Realtime-PCR)
- Brucella: Nachweis (PCR)
- Chlamydiatrachomatis: Nachweis (Realtime-PCR)
- Chlamydiapneumoniae: Nachweis (Realtime-PCR)
- Clostridium difficile: Nachweis + Toxinbildung (Realtime-PCR)
- Francisellatularensis: Nachweis (Realtime-PCR)
- Helicobacterpylori: Nachweis (Realtime-PCR)
- Listeria: Nachweis (Realtime-PCR)
- Mycobacteriumtuberculosis/MOTT: Nachweis + Typisierung (PCR, Hybridisierung)
- Staphylococcusaureus: Nachweis (Realtime-PCR)
- Staphylococcusepidermidis: Nachweis (Realtime-PCR)
- Streptococcus pyogenes: Nachweis (Realtime-PCR)
- Treponemapallidum: Nachweis (Realtime-PCR)
- Tropherymawhipplei: Nachweis (Realtime-PCR)
- Yersiniaenterocolitica: Nachweis (Realtime-PCR)
- Yersiniapseudotuberculosis: Nachweis (Realtime-PCR)
- Bakterien allgemein/Resistenzgentestung: NGS-Shot gun (in Koop. Mit PathoNext)
- Epstein-Barr-Virus (EBV): Nachweis (IHC, ISH, Realtime-PCR)
- Cytomegalievirus (CMV): Nachweis (Realtime-PCR)
- Herpes simplex -Virus (HSV 1 und 2): Nachweis (Realtime-PCR)
- Kaposi-Sarkom-assoziiertes-Herpesvirus 8 (HHV-8/KSHV): Nachweis (PCR)
- Humanes Papillomavirus (HPV): Nachweis + Typisierung (PCR, Hybridisierung)
- Merkelzell-Polyomavirus (MCPyV): Nachweis (PCR)
- Varizellazoster-Virus (VZV): Nachweis (Realtime-PCR)
- Toxoplasmagondii: Nachweis (Realtime-PCR)
- Leishmania: Nachweis (Realtime-PCR)
- Candida: Nachweis (Realtime-PCR)
- Pneumocystisjirovecii: Nachweis (PCR)
- Kryptokokkusneoformans: Nachweis (PCR)